Video Insights
Video Insights
Advertisement
Guido Marcucci, MDChronic Myeloid Leukemia | November 29, 2023
Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured.
View More
Lorinda Coombs, PhD, MSNMyeloma | November 21, 2023
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Magdalena Taube, PhDMyeloma | October 26, 2023
Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery.
Anne Sophie Kubasch, MDVideo Insights | October 25, 2023
Anne Sophie Kubasch, MD, of Leipzig University, speaks on the importance of MDS World Awareness Day.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | October 24, 2023
Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.”
Talha Badar, MBBS, MDMyelodysplastic Syndromes | October 23, 2023
Across the entire study population, the two most frequent U2AF1 variants were S34F (n=97) and Q157P (n=46).
Advertisement
Sagar Lonial, MD, FACPVideo Insights | October 11, 2023
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
Thomas Martin, MDVideo Insights | October 5, 2023
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
Thomas Martin, MDVideo Insights | October 5, 2023
The panel discusses optimal dosing for teclistamab.
Thomas Martin, MDVideo Insights | October 5, 2023
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
Sagar Lonial, MD, FACPVideo Insights | October 5, 2023
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
Thomas Martin, MDVideo Insights | October 5, 2023
The panel continues the conversation around toxicity management for bispecific agents.
Sagar Lonial, MD, FACPVideo Insights | October 5, 2023
The panel compares clinical trial and real-world data for CAR-Ts.
Sagar Lonial, MD, FACPVideo Insights | October 4, 2023
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Sagar Lonial, MD, FACPVideo Insights | October 4, 2023
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
Nitin Jain, MDMeeting News | October 4, 2023
Nitin Jain, MD, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, to discuss unmet needs in CLL.
Thomas Martin, MDVideo Insights | October 3, 2023
The panel addresses side effects that are commonly seen in patients receiving bispecifics.
Thomas Martin, MDVideo Insights | October 3, 2023
The panel discusses their personal experience with bispecifics-related REMS programs.
Sagar Lonial, MD, FACPVideo Insights | October 2, 2023
The panel discusses which patients may not be suitable for CAR T-cell therapy.
Thomas Martin, MDVideo Insights | October 2, 2023
The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.
Advertisement
Advertisement
Editorial Board